Lilly's oral GLP-1, orforglipron, delivers weight loss of up to an average of 27.3 lbs in first of two pivotal Phase 3 trials in adults with obesity In ATTAIN-1, the investigational once-daily oral pill showed significant efficacy, and a safety and tolerability profile consistent with injectable GLP-1 therapies at 72 weeks Orforglipron achieved the primary and all key secondary endpoints, including demonstrating improvements in a number of cardiovascular risk factors With these results, Lilly is on track to submit orforglipron to global regulatory agencies by year-end and is making substantial investments to meet anticipated demand at launch 1 "Obesity is one of the most pressing global health challenges of our time, driving global chronic disease burden and impacting more than one billion people worldwide," said In the ATTAIN-1 trial, orforglipron met the primary endpoint of superior body weight reduction compared to placebo

At CYMBIOTIKA, our mission is to empower you with the knowledge and high-quality tools needed to take charge of your health
However, its safety profile is closely tied to timing, formulation, and individual risk factors
Weighing yourself once a week can provide valuable feedback and help you stay mindful of your habits and their impact on your body composition